* * * * * * * * * * Welcome to STN International
`
`* * * * * * * * * *
`
`NEWS
`NEWS
`
`NEWS
`NEWS
`
`NEWS
`NEWS
`
`NEWS
`
`NEWS
`
`7 Search Limits Significantly Expanded Exclusively in STNext(R)
`1 MAR
`2
`APR 18 New legal status codes for US patent applications and
`granted patents in INPADOC
`APR 30 Derwent Markush Resource (DWPIM) Database Enhancements
`OCT
`7 New CAS FORMULATIONS TM Database Launched on STNext
`
`3
`4
`
`5
`6
`
`7
`
`8
`
`OCT
`NOV
`
`8 Third 2019 update to Emtree(TM) now available on STN(R)
`8 Derwent Markush Resource (DWPIM) Enhanced to Improve Search
`and Retrieval Quality
`INPADOC Enhanced with More Current and Complete Japanese Legal
`Status Information.
`NOV 18 German Patent Full—Text Database DEFULL enhanced
`
`NOV 15
`
`9
`NEWS
`NEWS 10
`NEWS 11
`
`NEWS 12
`
`CAS FORMULATIONS (TM) Enhanced on STNext
`NOV 25
`NOV 25 PatentPak(R) now available in USPATFULL/USPAT2 on STNext(R)
`DEC 10 CAplus (SM) Now Provides Non—Conventional Patent Families
`for Chinese Dual Filings
`DEC 23 Derwent World Patents Index: Manual Code Revision 2020
`
`NEWS HOURS
`NEWS LOGIN
`
`STN Operating Hours Plus Help Desk Availability
`Welcome Banner and News Items
`
`NEWS TRAINING Find instructor—led and self—directed training opportunities
`
`Enter NEWS followed by the item number or name to see news on that
`specific topic.
`
`For pricing information enter HELP PRICE or HELP COST at any arrow prompt.
`
`All use of STN is subject to the provisions of the STN customer
`agreement. This agreement limits use to scientific research. Use
`for software development or design,
`implementation of commercial
`gateways, or use of CAS and STN data in the building of commercial
`products is prohibited and may result in loss of user privileges
`and other penalties.
`
`Access the latest version of STN.
`
`Log into STNext with your STN login ID at https:ffwww.stn.org
`
`STNext is updated frequently. To see the latest STNext Release Notes, click
`
`https:f/www.stn.orgfhelpfstnext/ReleaseNotes.htm
`
`* * * * * * * * * * * * * * STN Columbus
`
`* * * * * * * * * * * * * * *
`
`FILE 'HOME' ENTERED AT 11:29:31 ON 22 JAN 2020
`
`=> fil caplus
`
`COST IN U.S. DOLLARS
`
`FULL ESTIMATED COST
`
`SINCE FILE
`ENTRY
`0.18
`
`TOTAL
`SESSION
`0.18
`
`FILE 'CAPLUS' ENTERED AT 11:30:00 ON 22 JAN 2020
`USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
`
`COPYRIGHT (C) 2020 AMERICAN CHEMICAL SOCIETY (ACS)
`
`Copyright of the articles to which records in this database refer is
`held by the publishers listed in the PUBLISHER (PB) field (available
`for records published or updated in Chemical Abstracts after December
`26, 1996), unless otherwise indicated in the original publications.
`
`The CA Lexicon is the copyrighted intellectual property of the
`American Chemical Society and is provided to assist you in searching
`databases on STN. Any dissemination, distribution, copying, or storing
`of this information, without the prior written consent of CAS,
`is
`strictly prohibited.
`
`FILE COVERS 1907 - 22 Jan 2020 VOL 172 ISS 6
`
`FILE LAST UPDATED: 21 Jan 2020 (20200121/ED)
`
`

`

`REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2015
`USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2015
`
`CAplus now includes the comprehensive Cooperative Patent Classification
`(CPC).
`See HELP CPC for details.
`
`CAS Information Use Policies apply and are available at:
`
`http:f/www:cas.orgflegal/infopclicy
`
`This file contains CAS Registry Numbers for easy and accurate
`substance identification.
`
`=> s (("chlorguanide") or ("chloroguanide") or ("malarone") or ("proguanil"))
`
`57 "CHLORGUANIDE"
`69 "CHLOROGUANIDE"
`114 "MALARONE"
`1011 "PROGUANIL"
`1
`"PROGUANILS"
`1012 "PROGUANIL"
`
`L1
`
`("PROGUANIL" OR "PROGUANILS")
`1149 (("CHLORGUANIDE") OR ("CHLOROGUANIDE") OR ("MALARONE") OR ("PROG
`UANIL"))
`
`=> s (("hair") or ("cuticle") or ("scalp") or ("skin") or ("dermal") or ("dermis")
`or ("epidermis") or ("follicle"))
`
`151115 "HAIR"
`10051 "HAIRS"
`155605 "HAIR"
`
`("HAIR" OR "HAIRS")
`15305 "CUTICLE"
`1995 "CUTICLES"
`15970 "CUTICLE"
`
`("CUTICLE" OR "CUTICLES")
`12878 "SCALP"
`192 "SCALPS"
`12980 "SCALP"
`
`("SCALP" OR "SCALPS")
`649482 "SKIN"
`18078 "SKINS"
`658722 "SKIN"
`
`("SKIN" OR "SKINS")
`40996 "DERMAL"
`18987 "DERMIS"
`9
`"DERMISES"
`18990 "DERMIS"
`
`("DERMIS" OR "DERMISES")
`56803 "EPIDERMIS"
`78 "EPIDERMISES"
`56833 "EPIDERMIS"
`
`("EPIDERMIS" OR "EPIDERMISES")
`62184 "FOLLICLE"
`31083 "FOLLICLES"
`73180 "FOLLICLE"
`
`L2
`
`("FOLLICLE" OR "FOLLICLES")
`887461 (("HAIR") OR ("CUTICLE") OR ("SCALP") OR ("SKIN") OR ("DERMAL")
`OR ("DERMIS") OR ("EPIDERMIS") OR ("FOLLICLE"))
`
`:> s Ll
`
`(L) L2
`
`L3
`
`11 L1 (L) L2
`
`=> display L3 l—ll ibib abs hitstr
`
`ANSWER 1 OF 11
`L3
`ACCESSION NUMBER:
`DOCUMENT NUMBER:
`
`COPYRIGHT 2020 ACS on STN
`CAPLUS
`2019:936868
`CAPLUS Fullwtext
`171:67748
`
`

`

`TITLE:
`
`Initial Development toward Non—Invasive Drug
`Monitoring via Untargeted Mass Spectrometric Analysis
`of Human Skin
`
`AUTHOR(S):
`
`CORPORATE SOURCE:
`
`SOURCE:
`
`Jarmusch, Alan K.; Elijah, Emmanuel 0.; Vargas,
`Fernando; Bouslimani, Amina; da Silva, Ricardo R.;
`Ernst, Madeleine; Wang, Mingxun; del Rosario, Krizia
`K.; Dorrestein, Pieter C.; Tsunoda, Shirley M.
`Skaggs School of Pharmacy and Pharmaceutical Sciences,
`University of California, La Jolla, CA, 92093, USA
`Analytical Chemistry (Washington, DC, United States)
`(2019), 91(13), 8062—8069
`CODEN: ANCHAM;
`ISSN: 0003—2700
`10.lOZl/acs.analchem.8b05854
`DIGITAL OBJECT ID:
`American Chemical Society
`PUBLISHER:
`Journal;
`(online computer file)
`DOCUMENT TYPE:
`English
`LANGUAGE:
`AB
`Drug monitoring is crucial for providing accurate and effective care;
`however, current methods (e.g., blood draws) are inconvenient and
`unpleasant. We aim to develop a non—invasive method for the detection and
`monitoring of drugs via human skin.
`The initial development toward this
`aim required information about which drugs,
`taken orally, can be detected
`via the skin. Untargeted liq. chromatog.—mass spectrometry (LC—MS) was
`used as it was unclear if drugs, known drug metabolites, or other
`transformation products were detectable.
`In accomplishing our aim, we
`analyzed samples obtained by swabbing the skin of 15 kidney transplant
`recipients in five locations (forehead, nasolabial area, axillary,
`backhand, and palm), bilaterally, on two different clin. visits.
`Untargeted LC—MS data were processed using mol. networking via the Global
`Natural Products Social Mol. Networking platform. Herein, we report the
`qual. detection and location of drugs and drug metabolites.
`For example,
`escitalopram/citalopram and diphenhydramine,
`taken orally, were detected
`in forehead, nasolabial, and hand samples, whereas
`N—acetyl—sulfamethoxazole, a drug metabolite, was detected in axillary
`samples.
`In addn., chems. assocd. with environmental exposure were also
`detected from the skin, which provides insight into the multifaceted chem.
`influences on our health.
`The proof—of—concept results presented support
`the finding that the LC—MS and data anal. methodol.
`is currently capable
`of the qual. assessment of the presence of drugs directly via human skin.
`OS.CITING REF COUNT:
`1
`THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
`
`REFERENCE COUNT:
`
`30
`
`(1 CITINGS)
`THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS
`RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
`
`ANSWER 2 OF 11
`L3
`ACCESSION NUMBER:
`DOCUMENT NUMBER:
`
`COPYRIGHT 2020 ACS on STN
`CAPLUS
`2018:937379
`CAPLUS Full text
`169:11364
`
`TITLE:
`
`INVENTOR(S):
`
`Application of proguanil in preparation of antitumor
`drug
`Yang, Xiaoping; Da, Keou; Tang, Bixi; Deng, Jun; He,
`Caimei; Tao, Ting; Huang, Yanjun; Su, Qiongli; Peng,
`Mei
`
`PATENT ASSIGNEE(S):
`SOURCE:
`
`DOCUMENT TYPE:
`LANGUAGE:
`FAMILY ACC. NUM. COUNT:
`PATENT INFORMATION:
`PATENT NO.
`
`Hunan Normal University, Peop. Rep. China
`Faming Zhuanli Shenqing, 12pp.
`CODEN: CNXXEV
`Patent
`Chinese
`1
`
`KIND DATE
`
`APPLICATION NO.
`
`DATE
`
`CN 108030777
`CN 108030777
`PRIORITY APPLN.
`INFO.:
`
`A
`B
`
`20180515
`20191112
`
`CN 2017-11270053
`
`20171205
`
`CN 2017-11270053
`
`20171205
`
`CASFORMULTNS 2018:937379
`OTHER SOURCE(S):
`AB
`The invention discloses application of pregaanil in prepn. of antitumor
`drug, and drug for inhibiting primary growth and/or metastatic growth of
`tumor.
`The tumor is malignant tumor or benign tumor.
`The malignant tumor
`comprises one or more of bladder tumor, melanoma, breast tumor,
`non—Hodgkin lymphoma, colorectal cancer, pancreatic cancer, endometrial
`cancer, prostate cancer, renal carcinoma, renal cell cancer, non—melanoma
`skin cancer,
`leukemia,
`thyroid cancer,
`lung cancer, cervical cancer,
`
`

`

`ovarian cancer, testicular cancer, and central nervous system tumors.
`drug is single component of praguanil, or drug compn., drug mixt. or
`mol. structure modifier contg. effect dose of prcguanil.
`The
`praguanil has strong tumor—inhibiting effect through key protein AMPK in
`energy metab. of targeted tumor cells, and the effect for treating tumor
`is better than N—(4—fluorophenyl)biguanide, metformin and other biguanide
`drugs.
`
`The
`
`ANSWER 3 OF 11
`L3
`ACCESSION NUMBER:
`DOCUMENT NUMBER:
`
`COPYRIGHT 2020 ACS on STN
`CAPLUS
`2017:1338287
`CAPLUS Fullutext
`167:294615
`
`TITLE:
`
`INVENTOR(S):
`
`PATENT ASSIGNEE(S):
`SOURCE:
`
`DOCUMENT TYPE:
`
`LANGUAGE:
`FAMILY ACC. NUM. COUNT:
`PATENT INFORMATION:
`PATENT NO.
`
`Melanin decomposition inhibitor, autophagy inhibitor,
`hair coloring agent and skin external preparation
`containing plant extract
`Murase, Daiki; Hachiya, Akira; Oya, Naoki; Takano,
`Kei; Kawasaki, Akiko; Kawabata, Keigo
`Kao Corporation, Japan
`PCT Int. Appl., 62pp.
`CODEN: PIXXD2
`Patent
`
`Japanese
`1
`
`KIND DATE
`
`APPLICATION NO.
`
`DATE
`
`20170210
`W0 2017—JP4987
`20170817
`A1
`WO 2017138652
`w:
`AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
`BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC,
`EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU,
`ID,
`IL,
`IN,
`IR,
`IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS,
`LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
`NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD,
`SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA,
`UG, US, UZ, VC, VN, ZA, ZM,
`zw
`RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR,
`HU,
`IE,
`IS,
`IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS,
`SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM,
`ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW,
`SD, SL, ST, SZ, TZ, UG, ZM, zw, AM, AZ, BY, KG, KZ, RU, TJ, TM
`CN 108697706
`A
`20181023
`CN 20 7—80011011
`20170210
`EP 3415147
`A1
`20181219
`EP 2017—750373
`20170210
`R:
`AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR,
`HU,
`IE,
`IS,
`IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO,
`RS, SE, SI, SK, SM, TR, BA, ME
`US 20190053994
`A1
`20190221
`PRIORITY APPLN.
`INFO.:
`
`US 2018-16075828
`P
`US 2016-62294667
`A
`JP 2016-217082
`W
`WO 2017-JP4987
`ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMA
`I-ZI
`
`20180806
`20160212
`20161107
`20170210
`
`CASFORMULTNS 2017:1338287
`OTHER SOURCE(S):
`AB
`Provided is a melanin decompn.
`inhibitor in keratinocytes to accelerate
`the accumulation of melanin in skin and hair, which contains at least
`one component selected from a plant ext. contg. berberine or a salt
`thereof, berberine or a salt thereof, prognanil or a salt thereof and
`phenformin or a salt thereof as an active ingredient. According to the
`present invention, it is possible to provide a melanin decompn.
`inhibitor
`which can inhibit the decompn. of melanin in keratinocytes to accelerate
`the accumulation of melanin in Skin and hair.
`REFERENCE COUNT:
`5
`THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
`RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
`
`ANSWER 4 OF 11
`L3
`ACCESSION NUMBER:
`DOCUMENT NUMBER:
`
`COPYRIGHT 2020 ACS on STN
`CAPLUS
`2012:182895
`CAPLUS Fullmtext
`157:599521
`
`TITLE:
`
`AUTHOR(S):
`
`Genetic polymorphisms and drug susceptibility in four
`isolates of Leishmania tropica obtained from Canadian
`soldiers returning from Afghanistan
`Plourde, Marie; Coelho, Adriano; Keynan, Yoav; Larios,
`Oscar E.; Ndao, Momar; Ruest, Annie; Roy, Gaetan;
`Rubinstein, Ethan; Ouellette, Marc
`
`

`

`SOURCE:
`
`CORPORATE SOURCE:
`
`Centre de Recherche en Infectiologie du Centre de
`Recherche du CHUQ and Departement de Microbiologie,
`Immunologie et Infectiologie, Faculte de Medecine,
`Universite Laval, Quebec, QC, Can.
`PLoS Neglected Tropical Diseases (2012), 6(1), el463
`CODEN: PNTDAM;
`ISSN: 1935-2735
`10.137l/journal.pntd.0001463
`DIGITAL OBJECT ID:
`Public Library of Science
`PUBLISHER:
`Journal;
`(online computer file)
`DOCUMENT TYPE:
`English
`LANGUAGE:
`AB
`Cutaneous leishmaniasis (CL) is a vector—borne parasitic disease
`characterized by the presence of one or more lesions on the skin that
`usually heal spontaneously after a few months. Most cases of CL worldwide
`occur in Southwest Asia, Africa and South America, and a no. of cases have
`been reported among troops deployed to Afghanistan.
`No vaccines are
`available against this disease, and its treatment relies on chemotherapy.
`The aim of this study was to characterize parasites isolated from Canadian
`soldiers at the mol.
`level and to det. their susceptibility profile
`against a panel of antileishmanials to identify appropriate therapies.
`Parasites were isolated from Skin lesions and characterized as
`
`Leishmania tropica based on their pulsed field gel electrophoresis
`profiles and pteridine reductase l
`(PTRl) sequences. Unusually high
`allelic polymorphisms were obsd. at several genetic loci for the L.
`tropica isolates that were characterized.
`The drug susceptibility profile
`of intracellular amastigote parasites was detd. using an established
`macrophage assay. All isolates were sensitive to miltefosine,
`amphotericin B, sodium stibogluconate (Pentostam) and paromomycin, but
`were not susceptible to fluconazole. Variable levels of susceptibility
`were obsd. for the antimalarial agent atovaquone/proguanil (Malarcne).
`Three Canadian soldiers from this study were successfully treated with
`miltefosine. This study shows high heterogeneity between the two L.
`tropica allelic versions of a gene but despite this, L.
`tropica isolated
`from Afghanistan are susceptible to several of the antileishmanial drugs
`available.
`OS.CITING REF COUNT:
`
`THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
`
`6
`
`REFERENCE COUNT:
`
`40
`
`(6 CITINGS)
`THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS
`RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
`
`ANSWER 5 OF 11
`L3
`ACCESSION NUMBER:
`DOCUMENT NUMBER:
`
`COPYRIGHT 2020 ACS on STN
`CAPLUS
`2009:1403024
`CAPLUS Fullwtext
`151:515314
`
`TITLE:
`
`INVENTOR(S):
`PATENT ASSIGNEE(S):
`SOURCE:
`
`DOCUMENT TYPE:
`
`LANGUAGE:
`FAMILY ACC. NUM. COUNT:
`PATENT INFORMATION:
`PATENT NO.
`
`Pharmaceutical compositions containing prsguanil to
`treat skin/mucosal diseases
`Godowski, Kenneth
`Tolmar, Inc., USA
`PCT Int. Appl., 82 pp.
`CODEN: PIXXD2
`Patent
`
`English
`1
`
`KIND DATE
`
`APPLICATION NO.
`
`DATE
`
`WO 2009-US2879
`
`20090508
`
`20091112
`A2
`WO 2009137100
`20100722
`A3
`WO 2009137100
`w:
`AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
`CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
`FI, GB, GD, GE, GH, GM, GT, HN, HR, HU,
`ID,
`IL,
`IN,
`IS, JP, KE,
`KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
`ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
`PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
`TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
`ZW
`RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
`IE,
`IS,
`IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
`SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
`TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
`ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
`AU 2009244819
`A1
`20091112
`AU 2009—24481
`US 20090280069
`A1
`20091112
`US 2009—463028
`EP 2273974
`A2
`20110119
`EP 2009—743087
`
`20090508
`20090508
`20090508
`
`

`

`R:
`
`AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
`IE,
`IS,
`IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE,
`SI, SK, TR, AL, BA, RS
`KR 2011010763
`A
`20110207
`CN 102088956
`A
`20110608
`BR 2009008701
`A2
`20150721
`MX 2010012261
`A
`20110407
`IN 2010CN07354
`A
`20110826
`PRIORITY APPLN.
`INFO.:
`
`KR 2010-7027567
`CN 2009-80126528
`BR 2009-8701
`MX 2010-12261
`IN 2010-CN7354
`P
`US 2008-61051812
`W
`WO 2009-US2879
`ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
`
`20090508
`20090508
`20090508
`20101109
`20101115
`20080509
`20090508
`
`CASFORMULTNS 2009:1403024
`OTHER SOURCE(S):
`AB
`Proguanil has been found to have rapid and effective killing activity
`against a variety of disease—causing microorganisms.
`For example, when
`applied topically, proguanil is particularly effective against
`Propionibacterium acnes, a bacteria that causes acne; Corynebacterium
`minutissimum, a bacteria that causes erythrasma, Gardnerella vaginalis, a
`bacteria that causes vaginosis; Trichomonas vaginalis, a protozoan that
`causes trichomoniasis and C. albicans, a fungus (a form of yeast).
`A
`topical lotion contained proguanil hydrochloride 10, emulsifying wax 50,
`iso—Pr myristate 50, Polysorbate—60 10, propylene glycol 170, and purified
`water q.s. 1000 g.
`OS.CITING REF COUNT:
`
`THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
`
`1
`
`(1 CITINGS)
`
`ANSWER 6 OF 11
`L3
`ACCESSION NUMBER:
`
`DOCUMENT NUMBER:
`
`COPYRIGHT 2020 ACS on STN
`CAPLUS
`2008:1514986
`CAPLUS
`Correction of: 2008:1322701 Full—text
`150:89826
`Correction of: 149:548337
`
`TITLE:
`
`AUTHOR(S):
`
`CORPORATE SOURCE:
`
`SOURCE:
`
`DIGITAL OBJECT ID:
`PUBLISHER:
`
`Ototoxicity of artemether/lumefantrine in the
`treatment of falciparum malaria: a randomized trial
`Guerkov, Robert; Eshetu, Teferi; Miranda, Isabel
`Barreto; Berens—Riha, Nicole; Mamo, Yoseph; Girma,
`Tsinuel; Krause, Eike; Schmidt, Michael; Hempel,
`John—Martin; Loescher, Thomas
`Department of Otorhinolaryngology Head and Neck
`Surgery, Ludwig Maximilians University, Munich,
`Germany
`Malaria Journal (2008), 7, No pp. given
`CODEN: MJAOAZ;
`ISSN: 1475-2875
`URL: http:{/www.malariajournal.comlcontent,pdf/1475w
`2875w7m179.pdf
`10.1186/1475-2875-7-179
`BioMed Central Ltd.
`
`(online computer file)
`
`Journal;
`DOCUMENT TYPE:
`English
`LANGUAGE:
`AB
`Due to increasing drug resistance, artemisinin—based combination
`chemotherapy (ACT) has become the first—line treatment of falciparum
`malaria in many endemic countries. However,
`irreversible ototoxicity
`assocd. with artemether/lumefantrine (AL) has been reported recently and
`suggested to be a serious limitation in the use of ACT.
`The aim of the
`study was to compare ototoxicity, tolerability, and efficacy of ACT with
`that of quinine and atovaquone/proguanil in the treatment of
`uncomplicated falciparum malaria. Ninety—seven patients in south—west
`Ethiopia with slide—confirmed malaria were randomly assigned to receive
`either artemether/lumefantrine or quinine or atovaquone/proguanil and
`followed—up for 90 days. Comprehensive audiovestibular testing by pure
`tone audiometry (PTA),
`transitory evoked (TE) and distortion product
`(DP)
`otoacoustic emissions (OAE) and brain stem evoked response audiometry
`(BERA) was done before enrollment and after seven, 28 and 90 days.
`PTA
`and DP—OAE levels revealed transient significant cochlear hearing loss in
`patients treated with quinine but not in those treated with
`artemether/lumefantrine or atovaquone/proguanil.
`TE—OAE could be
`elicited in all examns., except for three patients in the Q group on day
`7, who suffered a transient hearing loss greater than 30 dB. There was no
`evidence of drug—induced brain stem lesions by BERA measurements. There
`was no detrimental effect of a std. oral regimen of
`artemether/lumefantrine on peripheral hearing or brainstem auditory
`pathways in patients with uncomplicated falciparum malaria.
`In contrast,
`transient hearing loss is common after quinine therapy and due to
`
`

`

`temporary outer hair cell dysfunction.
`REFERENCE COUNT:
`34
`THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS
`RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
`
`ANSWER 7 OF 11
`L3
`ACCESSION NUMBER:
`DOCUMENT NUMBER:
`
`COPYRIGHT 2020 ACS on STN
`CAPLUS
`2008:1322701
`CAPLUS Fullmtext
`149:548337
`
`TITLE:
`
`AUTHOR(S):
`
`CORPORATE SOURCE:
`
`SOURCE:
`
`DIGITAL OBJECT ID:
`PUBLISHER:
`
`Ototoxicity of artemether/lumefantrine in the
`treatment of falciparum malaria: a randomized trial
`Guerkov, Robert; Eshetu, Teferi; Miranda, Isabel
`Barreto; Berens—Riha, Nicole; Mamo, Yoseph; Girma,
`Tsinuel; Krause, Eike; Schmidt, Michael; Hempel,
`John—Martin; Loescher, Thomas
`Department of Otorhinolaryngology Head and Neck
`Surgery, Ludwig Maximilians University, Munich,
`Germany
`Malaria Journal (2008), 7, No pp. given
`CODEN: MJAOAZ;
`ISSN: 1475-2875
`URL: http://www.malariajournal.com/content,pdf/l475"
`2875~7~179.pdf
`10.1186/1475-2875-7-179
`BioMed Central Ltd.
`
`(online computer file)
`
`Journal;
`DOCUMENT TYPE:
`English
`LANGUAGE:
`AB
`Background: Due to increasing drug resistance, artemisinin—based
`combination chemotherapy (ACT) has become the first—line treatment of
`falciparum malaria in many endemic countries. However,
`irreversible
`ototoxicity assocd. with artemether/lumefantrine (AL) has been reported
`recently and suggested to be a serious limitation in the use of ACT.
`The
`aim of the study was to compare ototoxicity, tolerability, and efficacy of
`ACT with that of quinine and atovaquone/prcguanil in the treatment of
`uncomplicated falciparum malaria. Methods: Ninety—seven patients in
`south—west Ethiopia with slide—confirmed malaria were randomly assigned to
`receive either artemether/lumefantrine or quinine or
`atovaquone/prcguanil and followed—up for 90 days. Comprehensive
`audiovestibular testing by pure tone audiometry (PTA),
`transitory evoked
`(TE) and distortion product
`(DP) otoacoustic emissions (OAE) and brain
`stem evoked response audiometry (BERA) was done before enrollment and
`after seven, 28 and 90 days. Results: PTA and DP—OAE levels revealed
`transient significant cochlear hearing loss in patients treated with
`quinine but not in those treated with artemether/lumefantrine or
`atovaquone/proguanil.
`TE—OAE could be elicited in all examns., except
`for three patients in the Q group on day 7, who suffered a transient
`hearing loss greater than 30 dB. There was no evidence of drug—induced
`brain stem lesions by BERA measurements. Conclusion: There was no
`detrimental effect of a std. oral regimen of artemether/lumefantrine on
`peripheral hearing or brainstem auditory pathways in patients with
`uncomplicated falciparum malaria.
`In contrast,
`transient hearing loss is
`common after quinine therapy and due to temporary outer hair cell
`dysfunction.
`REFERENCE COUNT:
`
`34
`
`THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS
`RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
`
`ANSWER 8 OF 11
`L3
`ACCESSION NUMBER:
`DOCUMENT NUMBER:
`
`COPYRIGHT 2020 ACS on STN
`CAPLUS
`2002:892564
`CAPLUS Full~text
`138:100397
`
`TITLE:
`
`AUTHOR(S):
`
`CORPORATE SOURCE:
`
`SOURCE:
`
`DIGITAL OBJECT ID:
`PUBLISHER:
`DOCUMENT TYPE:
`
`Tolerability of doxycycline monohydrate salt vs.
`chloroquine—proguanil in malaria chemoprophylaxis
`Pages, Frederic; Boutin, Jean—Paul; Meynard,
`Jean—Baptiste; Keundjian, Annick; Ryfer, Serge;
`Giurato, Luciano; Baudon, Dominique
`Institut de Medecine Tropicale du Service de Sante des
`Armees (IMTSSA), Le Pharo Marseille, Fr.
`Tropical Medicine & International Health (2002),
`7(11), 919—924
`ISSN: 1360—2276
`CODEN: TMIHFL;
`lO.lO46/j.1365-3156.2002.0094l.x
`Blackwell Science Ltd.
`Journal
`
`LANGUAGE:
`
`English
`
`

`

`AB
`
`The resistance of Plasmodium falciparum to the chloroquine—pregaanil
`assocn.
`(C/P) as antimalarial chemoprophylaxis is becoming increasingly
`common in Africa. Daily oral doxycycline hyclate 100 mg is effective as
`malaria prophylaxis. But the hyclate salt's adverse effects combined with
`the capsule's galenic form are incompatible with good chemoprophylaxis
`compliance. We conducted a randomized group study of 522 French soldiers
`deployed in Gabon and Chad for 4 mo to det.
`the tolerability of short—term
`malaria chemoprophylaxis with a 100—mg daily tablet of a monohydrate
`doxycycline salt compared with a daily C/P capsule. At days 7 and 120,
`compliance was better in the doxycycline group [resp. 98.5% vs. 73.9% (P <
`0.001) and 90.5% vs.
`74% (P < 0.001)].
`No major event (evacuation,
`hospitalization) was related to the medications. Epigastralgia, diarrhea,
`urticaria, mouth ulcers, sun sensitization and desquamation were
`significantly more frequent in the C/P group (P < 0.05). There was no
`statistical difference for malaria incidence, vertigo, nausea and hair
`loss.
`These results suggest that doxycycline monohydrate may be safely
`used in short—term malaria chemoprophylaxis. With the same efficacy as a
`hyclate doxycycline, doxycycline monohydrate could be a good
`chemoprophylaxis for short—term travelers at particular risk of C/P
`resistant P.
`falciparum malaria.
`OS.CITING REF COUNT:
`9
`THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD
`
`REFERENCE COUNT:
`
`11
`
`(9 CITINGS)
`THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
`RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
`
`ANSWER 9 OF 11
`L3
`ACCESSION NUMBER:
`DOCUMENT NUMBER:
`
`COPYRIGHT 2020 ACS on STN
`CAPLUS
`1999:379560
`CAPLUS Full~text
`131:179346
`
`TITLE:
`
`AUTHOR(S):
`
`CORPORATE SOURCE:
`
`SOURCE:
`
`PUBLISHER:
`DOCUMENT TYPE:
`
`Safety and efficacy of atovaquone and proguanil
`hydrochloride for the prophylaxis of Plasmodium
`falciparum malaria in South Africa
`Van der Berg, J. Dirk; Duvenage, Cornelia S. J.;
`Roskell, Neil S.; Scott, Trevor R.
`Department of Internal Medicine,
`1 Military Hospital,
`Pretoria, S. Afr.
`Clinical Therapeutics (1999), 21(4), 741—749
`CODEN: CLTHDG;
`ISSN: 0149-2918
`Excerpta Medica
`Journal
`
`English
`LANGUAGE:
`the safety and efficacy of
`AB
`The objective of this study was to det.
`atovaquone and proguanil hydrochloride combination therapy for the
`prophylaxis of Plasmodium falciparum malaria in at—risk nonimmune subjects
`in South Africa. This open—label trial was conducted at research sites in
`South Africa during the main malaria transmission season, Feb.
`through
`July.
`The study volunteers were temporarily living in, or traveling to, a
`malaria—endemic area.
`They received 1 tablet of 250 mg atovaquone and 100
`mg pregaanil hydrochloride once daily for up to 10 wk. Subjects were
`monitored using sequential clin. and lab. assessments. Thick blood smears
`were stained and evaluated by a central lab.
`An immunochromatog. test for
`P falciparum was also used for on—site patient management. Prophylactic
`success was summarized using a 95% confidence interval for the proportion
`of subjects who did not develop parasitemia or who withdrew due to a
`treatment—related adverse event.
`A total of 175 subjects (15% women) were
`enrolled in the trial.
`The mean duration of drug exposure was 8.9 wk.
`The combination of atovaquone and proguanil hydrochloride was well
`tolerated.
`The most frequently reported adverse events considered
`possibly related to study treatment were headache (7%), abdominal pain
`(2%),
`increased cough (2%), and skin disorder (2%).
`No serious adverse
`events were reported, and no treatment—emergent effects were noted for any
`lab. variables.
`One subject who was noncompliant with therapy developed
`parasitemia, and 3 subjects withdrew due to a treatment—related adverse
`event
`(2 subjects with headache and 1 with nausea and dizziness).
`The
`prophylaxis success rate was 97%.
`In this study, atovaquone and
`prcguanil hydrochloride combination therapy had an excellent safety and
`efficacy profile for prophylaxis of P falciparum malaria in nonimmune
`subjects.
`OS.CITING REF COUNT:
`
`THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
`
`7
`
`REFERENCE COUNT:
`
`33
`
`(7 CITINGS)
`THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS
`RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
`
`

`

`ANSWER 10 OF 11
`L3
`ACCESSION NUMBER:
`DOCUMENT NUMBER:
`ORIGINAL REFERENCE NO.:
`TITLE:
`
`AUTHOR(S):
`CORPORATE SOURCE:
`SOURCE:
`
`DIGITAL OBJECT ID:
`PUBLISHER:
`DOCUMENT TYPE:
`
`COPYRIGHT 2020 ACS on STN
`CAPLUS
`1997:248850
`CAPLUS Full~fiext
`126:234520
`126:4528la,45284a
`Screening and identification of drugs in human hair by
`high—performance liquid
`chromatography—photodiode—array UV detection and gas
`chromatography—mass spectrometry after solid—phase
`extraction. A powerful tool in forensic medicine
`Gaillard, Yvan; Pepin, Gilbert
`Lab. d'Expertises TOXLAB, Paris, 75018, Fr.
`Journal of Chromatography A (1997), 762(1 + 2),
`251-267
`ISSN: 0021-9673
`JCRAEY;
`CODEN:
`lO.lOl6/S0021-9673(96)00707-8
`Elsevier
`Journal
`
`English
`LANGUAGE:
`AB
`A method is described to screen for a wide range of pharmaceuticals in
`human hair.
`Powd. hair (75 mg) are incubated (12 h at +56°)
`in 2
`mL of distd. water (acidic compds.) or 0.1 M hydrochloric acid (neutral
`and basic compds.).
`A twin solid—phase extn. on C18 cartridges is used
`for the sample clean—up procedure. Acidic drugs are fixed at pH 2 and
`eluted with 1% ammoniacal methanol while neutral and basic drugs are
`retained on the column at pH 8.5 and eluted with methanol contg. 0.5%
`acetic acid.
`The internal std. (I.S.) for the acidic extn. was
`bupivacaine while the I.S. for the basic extn. was prazepam.
`The sepn. of
`the drugs was performed using both the liq. and the gas chromatog.
`techniques whereas identification was achieved using photodiode array and
`mass spectrometric detection, resp.
`The liq. chromatog. system gives an
`elution of the drugs following a multi step gradient from a Symmetry C8
`(Waters) 5 um column (ZSOX4.6 mm I.D.) at +30° with
`acetonitrile—phosphate buffer (pH 3.8).
`Identification is achieved using
`the ref. data (retention times and spectra) of 675 pharmaceuticals,
`toxicants and drugs of abuse stored in a personal library.
`The present
`method has been applied during 6 mo in our lab.
`By establishing a
`victim's drug use history, it is a very powerful tool in forensic
`medicine. We illustrate the method with some real cases of police crime
`investigation.
`OS.CITING REF COUNT:
`
`THERE ARE 54 CAPLUS RECORDS THAT CITE THIS
`
`54
`
`REFERENCE COUNT:
`
`5l
`
`RECORD (55 CITINGS)
`THERE ARE 5l CITED REFERENCES AVAILABLE FOR THIS
`RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
`
`ANSWER 11 OF 11
`L3
`ACCESSION NUMBER:
`DOCUMENT NUMBER:
`ORIGINAL REFERENCE NO.:
`
`COPYRIGHT 2020 ACS on STN
`CAPLUS
`1953:26364
`CAPLUS Fullwtext
`47:26364
`47:4502b—e
`
`TITLE:
`
`AUTHOR(S):
`CORPORATE SOURCE:
`SOURCE:
`
`DOCUMENT TYPE:
`LANGUAGE:
`
`Pharmacological properties of
`2,4—diamino—5—p—chlorophenyl—6—ethylpyrimidine
`(daraprim)
`Ida G.
`Schmidt, L. H.; Hughes, Hettie B.; Schmidt,
`Christ Hosp. Inst. Med. Research, Cincinnati, 0.
`Journal of Pharmacology and Experimental Therapeutics
`(1953), 107, 92—130
`CODEN:
`JPETAB;
`ISSN: 0022-3565
`Journal
`Unavailable
`
`AB
`
`cf. preceding abstr. Daraprim (I) was absorbed slowly and completely from
`the gut in monkeys,
`the size of dose markedly influencing the time at
`which peak plasma levels occurred.
`Plasma and tissue I was detd. by a
`modification of the Brodie methyl orange method.
`I did not accumulate in
`plasma and was extensively metabolized, only 20% being recovered in urine
`(detd. spectrophotometrically).
`I was moderately localized in monkey and
`rat lung,
`liver, kidney, and spleen.
`For a given dose tissue concns. of I
`were generally slightly greater than those of chlcrguanide but far less
`than those of chloroquine.
`In the rat 190 mg./kg. daily was uniformly
`fatal, producing skin lesions,
`leucopenia, neutropenia, and exhaustion
`of the myeloid elements of femoral marrow; 100 mg./kg. suppressed growth
`
`

`

`but was not lethal; and 50 mg./kg. affected neither growth or survival.
`Slowly
`In the monkey 5 mg./kg. was lethal in repeated daily doses.
`progressing intoxication was characterized by general malaise, bronze
`pigmentation of the skin of face and chest, gingivitis,
`and dehydration.
`The
`Acute convulsive seizures were prominent at doses of 20 mg./kg.
`lymph nodes, adrenal cortex,
`pathology included lesions in the spleen,
`bone marrow, and kidney calyx of which the microscopic characteristics are
`described.
`OS.CITING REF COUNT:
`
`THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
`
`2
`
`(2 CITINGS)
`
`=> s (("glycolysis")) (L) (("inducer") or ("activator") or ("agonist") or ("modulat
`or") or ("inducing agent") or ("activating agent") or ("agonizing agent") or ("m
`odulating agent"))
`
`48610
`55958
`25868
`75949
`
`"GLYCOLYSIS"
`"INDUCER"
`"INDUCERS"
`"INDUCER"
`
`212829
`56257
`248817
`
`195058
`149436
`268129
`
`87635
`79710
`134472
`
`256886
`1
`256887
`
`("INDUCER" OR "INDUCERS")
`"ACTIVATOR"
`"ACTIVATORS"
`"ACTIVATOR"
`
`("ACTIVATOR" OR "ACTIVATORS")
`"AGONIST"
`"AGONISTS"
`"AGONIST"
`
`("AGONIST" OR "AGONISTS")
`"MODULATOR"
`"MODULATORS"
`"MODULATOR"
`
`("MODULATOR" OR "MODULATORS")
`"INDUCING"
`"INDUCINGS"
`"INDUCING"
`
`2102692
`3167091
`4358010
`
`("INDUCING" OR "INDUCINGS")
`"AGENT"
`"AGENTS"
`"AGENT"
`
`6434
`
`("AGENT" OR "AGENTS")
`"INDUCING AGENT"
`
`243326
`1
`243327
`
`("INDUCING"(W)"AGENT")
`"ACTIVATING"
`"ACTIVATINGS"
`"ACTIVATING"
`
`2102692
`3167091
`4358010
`
`("ACTIVATING" OR "ACTIVATINGS")
`"AGENT"
`"AGENTS"
`"AGENT"
`
`8814
`
`("AGENT" OR "AGENTS")
`"ACTIVATING AGENT"
`
`313
`2102692
`3167091
`4358010
`
`("ACTIVATING"(W)"AGENT")
`"AGONIZING"
`"AGENT"
`"AGENTS"
`"AGENT"
`
`("AGENT" OR "AGENTS")
`"AGONIZING AGENT"
`
`1
`
`129471
`2102692
`3167091
`4358010
`
`("AGONIZING"(W)"AGENT")
`"MODULATING"
`"AGEN